Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer
October 02 2023 - 8:00AM
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company
developing precision genetic medicines for both neuromuscular and
cardiac diseases, today announced the appointment of Gabriel
Brooks, M.D., as Chief Medical Officer.
“We are excited to welcome Dr. Brooks to Solid
Biosciences during this pivotal time in our company’s history,
advancing towards the clinic with our next generation gene therapy
for Duchenne and furthering our diversified pipeline of both
neuromuscular and cardiac gene therapies,” said Bo Cumbo, President
and Chief Executive Officer of Solid Biosciences. “Dr. Brooks’
impressive accomplishments, specifically in cardiovascular genetic
medicine, will bring valuable expertise and insights to our
leadership team. His broad experience in precision genetic medicine
will be vital to Solid as we work to bring hope to those patients
living with these devastating genetic diseases.”
Prior to joining Solid Biosciences, Dr. Brooks
was Rare Cardiovascular Therapeutic Area Head in the Rare Disease
Research Unit at Pfizer. While there, he directed the translational
development of a range of precision AAV gene therapies for dilated,
arrhythmogenic, and hypertrophic cardiomyopathies. Additionally,
Dr. Brooks previously served as the vice president of research and
development at 4D Molecular Therapeutics, where he oversaw
translational development of AAV gene therapies for Anderson Fabry
and oversaw first-in-human dosing of AAV gene therapies for two
ophthalmologic indications (choroideremia and X-linked retinitis
pigmentosa). Previously, Dr. Brooks led a successful Phase III
registrational study of flurpiridaz at GE Life Sciences, and led
several cardiovascular clinical trials in rare and large market
indications while at Gilead Life Sciences.
“I am honored to be joining Solid Biosciences at
this exciting time in their evolution from a Duchenne focused
company to a true platform gene therapy company with a diversified
pipeline of neuromuscular and cardiac programs,” said Dr. Brooks.
“Solid has a tremendous legacy of leadership in the gene therapy
field and is deeply committed to developing and manufacturing novel
gene therapies. I look forward to working with my new colleagues to
realize the full potential of our pipeline and bring meaningful
treatments to patients in serious need.”
Dr. Brooks received a Bachelor of Science in
Biology from Carnegie Mellon University, a Doctor of Medicine from
Cornell University and a Master of Applied Sciences of
Biostatistics and Epidemiology from the University of California,
San Francisco. He completed his training in Internal Medicine at
Johns Hopkins Hospital, Baltimore, and fellowships in general
Cardiology and Advanced Imaging at the University of California,
San Francisco.
About Solid BiosciencesSolid
Biosciences is a life science company focused on advancing a
portfolio of both neuromuscular and cardiac programs, including
SGT-003, a differentiated gene therapy candidate for the treatment
of Duchenne muscular dystrophy (Duchenne), AVB-401, a gene therapy
program for the treatment of BAG3 mediated dilated cardiomyopathy,
AVB-202-TT, a gene therapy program for the treatment of
Friedreich’s Ataxia, and additional assets for the treatment of
fatal cardiac diseases. Solid aims to be the center of excellence
across a given disease spectrum bringing together those with
expertise in science, technology, disease management, and care.
Patient-focused and founded by those directly impacted, Solid’s
mandate is to improve the daily lives of patients living with these
devastating diseases. For more information, please visit
www.solidbio.com.
Forward-Looking StatementsThis
press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements regarding future expectations, plans and
prospects for the company; the ability to successfully achieve and
execute on the Company’s priorities and achieve key clinical
milestones; the Company’s SGT-003 program and the Company’s future
development of preclinical and capsid programs; and other
statements containing the words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “would,”
“working” and similar expressions. Any forward-looking statements
are based on management’s current expectations of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in, or implied by, such forward-looking statements. These
risks and uncertainties include, but are not limited to, risks
associated with the ability to recognize the anticipated benefits
of Solid’s acquisition of AavantiBio; the Company’s ability to
advance SGT-003, AVB-202-TT, AVB-401 and other preclinical programs
and capsid libraries on the timelines expected or at all; obtain
and maintain necessary approvals from the FDA and other regulatory
authorities; replicate in clinical trials positive results found in
preclinical studies of the Company’s product candidates; obtain,
maintain or protect intellectual property rights related to its
product candidates; compete successfully with other companies that
are seeking to develop Duchenne and other neuromuscular and cardiac
treatments and gene therapies; manage expenses; and raise the
substantial additional capital needed, on the timeline necessary,
to continue development of SGT-003, AVB-202-TT, AVB-401 and other
candidates, achieve its other business objectives and continue as a
going concern. For a discussion of other risks and uncertainties,
and other important factors, any of which could cause the Company’s
actual results to differ from those contained in the
forward-looking statements, see the “Risk Factors” section, as well
as discussions of potential risks, uncertainties and other
important factors, in the Company’s most recent filings with the
Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
the Company’s views as of the date hereof and should not be relied
upon as representing the Company’s views as of any date subsequent
to the date hereof. The Company anticipates that subsequent events
and developments will cause the Company's views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so.
Solid Biosciences Contact:Leah MonteiroVP,
Investor Relations and
Communications617-821-4427lmonteiro@solidbio.com
Solid Biosciences (NASDAQ:SLDB)
Historical Stock Chart
From Apr 2024 to May 2024
Solid Biosciences (NASDAQ:SLDB)
Historical Stock Chart
From May 2023 to May 2024